Enterotoxigenic Escherichia coli (ETEC) strains, which colonize host small intestines and produce one or more enterotoxins, are a major cause of diarrheal disease (40). ETEC strains are responsible for hundreds of thousands of deaths each year worldwide, in addition to causing over one billion diarrheal episodes in immunocompromised individuals, international travelers, and deployed military personnel (14, 33, 38) . The virulence determinants of ETEC in diarrhea disease are bacterial adhesins (colonization factor antigens [CFAs] and E. coli surface antigens) and enterotoxins known as heatlabile (LT) and heat-stable (ST) toxins (5, 13, 26, 38, 41) . ETEC adhesins mediate initial bacterial attachment to host epithelial cells and subsequent colonization of small intestines. LT and ST type I (STa) enterotoxins disrupt fluid homeostasis and cause hypersecretion of fluid and electrolytes through activation of adenylate cyclase (by LT) or guanylate cyclase (by STa) in host small intestinal epithelial cells. Epidemiological and clinical studies indicated that approximately one-half of the ETEC strains isolated from diarrheal patients produce STa toxin only, one-quarter express LT toxin only, and one-quarter produce both toxins (13, 30, 
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Currently, there are no vaccines available to provide broadspectrum protection against ETEC diarrhea (5, 38) . Experimental antiadhesin vaccines showed some protection against ETEC strains (8, 12, 13, 23, 29) . However, experimental antiadhesin vaccines carrying CFA antigens inhibit colonization against only ETEC strains expressing same or homologous CFAs, but they are not effective against ETEC strains expressing heterogeneous CFAs. In addition, recent evidence suggests that adhesins may not function as protective antigens in the setting of naturally acquired infections and reinfections (5) . Consequently, there is increasing enthusiasm in developing antitoxin vaccines against ETEC (5, 38) . Antitoxin vaccines currently under development, however, largely target LT toxin. STa toxin has not been included because of its poor immunogenicity and potent toxicity. STa becomes immunogenic only after being chemically or genetically coupled to a strongly immunogenic carrier protein and presented as a fusion or chimeric antigen (10, 20, 31, 35, 46) . Although it was suggested that LT antigens, due to their adjuvant activity, may broad host immunity against ETEC diarrhea (11) , data from other experimental vaccine studies clearly indicated that induced anti-LT immunity provided protection only against LT-producing ETEC strains but not against STa-producing ETEC strains (9, 10) . As over two-thirds of ETEC diarrheal cases are caused by STa-producing ETEC strains (13, 15, 29, 41) , STa antigens must be included in developing broadly effective antitoxin vaccines against ETEC.
To be included as a vaccine component, STa must have its immunogenicity enhanced and its toxicity attenuated. The potent toxicity makes native STa unsuitable for the development of safe vaccines. Earlier studies indicated that shorter synthetic STa peptides or STa that had its disulfide bonds disrupted showed reduced toxicity (37) . It was also demonstrated that shorter synthetic STa peptides with the 12th, 13th, or 14th amino acid residue substituted exhibited substantial reduction in toxicity (17, 42) . In addition, our recent study showed that in three analogous but full-length porcine-type STa toxoids, pSTa 11 , pSTa 12 , and pSTa 13 , which had a single amino acid substitution at the 11th, 12th , and 13th residues, toxicity was eliminated or diminished (46) . Furthermore, when these STa toxoids were genetically fused to pLT 192 toxoid, the toxoid fusions enhanced STa immunogenicity and elicited protective anti-STa antibodies (46) .
The porcine-and human-type STa toxins are highly homologous, and they share a nearly identical toxicity domain (34) . We believe human-type STa toxoids would become immunogenic and would induce protective anti-STa immunity after being fused to a carrier protein. The primary goal of this study was to determine whether a modified full-length human-type STa elicits protective anti-STa antibodies after being fused to a full-length human-type LT 192 toxoid. In addition, we genetically fused the STa 13 toxoid gene to the LT 192 genes with different linkers or at different locations to examine if enhancement of anti-STa immunogenicity can be optimized.
MATERIALS AND METHODS
Bacterial strains and plasmids. E. coli strains and plasmids used in this study are listed in Table 1 . The ETEC prototype strain H10407 was used to isolate the eltAB genes (encoding LT AB ) and estA gene (encoding STa). The eltAB, LT, estA, and STa genes used in the experiments described below are of the human type. E. coli BL21 (GE Healthcare, Piscataway, NJ) was used as a host strain. Vectors pBR322 (Promega, Madison, WI) and pET28␣ (Invitrogen, Carlsbad, CA) were used to clone and express LT, LT 192 , STa, STa 13 , and LT 192 -STa 13 genes. All E. coli strains were cultured in LB or 2ϫ yeast extract-tryptone (YT) medium supplemented with kanamycin (30 g/ml) or ampicillin (50 g/ml).
Cloning and mutation of the LT and STa genes. The STa gene (estA) and LT genes (eltAB) were isolated from E. coli H10407 genomic DNA and PCR amplified with designed PCR primers STaNheI-F/STaEagI-R and LTNhe-F/ LTEagI-R, respectively (Table 2) . PCR was performed in a PTC-100 thermal cycler (Bio-Rad, Hercules, CA) and using Pfu DNA polymerase (Stratagene, La Jolla, CA). Amplified products were separated by gel electrophoresis, purified using a QIAquick gel extraction kit (Qiagen, Valencia, CA), and digested with NheI and EagI restriction enzymes (New England BioLabs, Ipswich, MA) as described previously (46) . Digested inserts and vector products (pBR322) were ligated with T4 DNA ligase (New England BioLabs), and ligation products were used to transform E. coli BL21 competent cells by standard electroporation (1) . Ampicillin-selected colonies were initially screened by PCR and then DNA sequenced to ensure that cloned LT and STa genes were inserted in the correct reading frame.
The cloned LT genes were mutated at the nucleotides encoding the 192nd amino acid residue, and the cloned STa gene was mutated at the 13th amino acid in a three-step PCR as described previously (46) . Briefly, PCRs using primers pBRNheI-F with LT 192 -R and LT 192 -F with pBREagI-R amplified the 5Ј and 3Ј regions of the eltAB genes, and PCRs using primers pBRNheI-F with STa 13 -R and STa 13 -F with pBREagI-R amplified the 5Ј and 3Ј ends of the estA gene, respectively. Then the two amplified products of each gene were overlapped using an SOE (splicing by overlapping extension) PCR to introduce a substitution for LT R192G and STa P13F , respectively. The mutated LT R192G and STa P13F genes were cloned into vector pBR322.
Construction of LT 192 -STa 13 toxoid fusion genes. The LT 192 and STa 13 genes were genetically fused in a three-PCR method described previously (46) . PCR primers (Table 2) were specifically designed to remove nucleotides encoding the transmembrane signal peptides of the eltA, eltB, and estA genes and the stop codon of the eltB gene and to add a linker to connect the mutated eltAB and the estA genes, which encode the mature peptides, for a single open reading frame. Three linkers, a Gly-Pro linker and a longer L linker described previously (46) and a SalI linker (5Ј-gGGCCGGTCGAC-3Ј), were used in fusion construction. The internal forward and reverse PCR primers designed to truncate nucleotides encoding transmembrane signal peptides consist of 10 to 15 nucleotides downstream of the transmembrane signal peptide and 20 nucleotides upstream of the same signal peptide. One PCR, using the 5Ј-end external forward primer and an internal reverse primer, amplified the fragment upstream of the target transmembrane signal peptide, and a second PCR, using the internal forward primer and the external 3Ј-end reverse primer, amplified the fragment downstream of the same signal peptide. The two amplified products were overlapped in an SOE PCR to generate a fusion that had the nucleotides encoding the transmembrane signal peptide truncated. As the external forward primer contained a NheI site and the external reverse primer had a BamHI site (Table 2) , PCR products were digested with NheI and BamHI and cloned into vector pET28␣ (Novagen, Madison, WI) to be expressed as 6His-tagged proteins.
LT 192 -STa 13 fusion protein expression. LT 192 -STa 13 fusion proteins expressed in E. coli BL21 cells were examined in a standard sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Fusion strains were grown overnight at 30°C in 200 ml of 2ϫ YT medium with kanamycin (30 g/ml). Overnight-grown cultures with equivalent amounts of bacteria (based on cell optical density) were pelleted by centrifugation and resuspended in 1 ml of bacterial protein extraction reagent (B-PER, in phosphate buffer; Pierce, Rockford, IL) for total protein extraction. Thirty microliters of total protein extracts 13 fusion proteins expressed in BL21 were examined in T-84 cells for stimulation of intracellular cyclic AMP (cAMP) and cGMP levels with direct cAMP and cGMP enzyme immunoassay (EIA) kits (Assay Design, Ann Arbor, MI) as described previously (46) . To ensure that BL21 cells are capable of secreting toxin proteins, we transformed the BL21 cells with LT and STa plasmids and included the LTand STa-positive BL21 strains in cAMP and cGMP assays.
In addition, toxic activity of LT 192 -STa 13 fusions was examined in a porcine ligated-gut-loop assay (43, 44) . Briefly, two 5-day old piglets were used and 21 loops at the ileum and jejunum sections were prepared from each piglet. Each loop was injected with 2 ϫ 10 9 CFU of overnight culture growth of each fusion strain, the positive H10407 strain, or a negative-control strain in the following order (with three repeats): fusion 1b, fusion 2b, fusion 3b, fusion 4b, fusion 5b, positive, negative. At 8 h postinoculation, each loop was measured for length (cm) and the amount of fluid accumulated (g) as described previously (46) .
Purification of 6His-tagged LT 192 -STa 13 fusion proteins and mouse immunization. The 6His-tagged LT 192 -STa 13 fusion proteins expressed by the fusion strains were extracted and used to immunize mice. Expressed 6His-tagged proteins were extracted using B-PER (Pierce), and purified to an estimated purity greater than 90% using nickel affinity chromatography. Briefly, overnight culture growth in 2ϫ YT medium was induced by adding 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) for 3 h, and then bacteria were harvested. Pellets were lysed in B-PER reagent and briefly sonicated. Total protein extracts from cell lysates were incubated with Ni-nitrilotriacetic acid (Ni-NTA) agarose, and the 6His-tagged fusion proteins were extracted according to the protocol for batch purification of 6His-tagged proteins (Qiagen).
Ten female adult BALB/c mice (Harlan, Indianapolis, IN) were immunized intraperitoneally with each purified 6His-tagged fusion protein in three independent experiments (3, 3, and 4 mice per group, for each antigen). One hundred micrograms of fusion proteins, in an equal volume of Freund's incomplete adjuvant (Sigma), was injected into each mouse in the group. Two booster injections followed at biweekly intervals. A group of mice injected with saline (and an equal volume of Freund's incomplete adjuvant) was used as the negative control. Blood samples were collected from each mouse before immunization and 14 days after each immunization. Fecal pellets were also collected and suspended in fecal reconstitution buffer with the protease inhibitor phenylmethylsulfonyl fluoride (Sigma) at a ratio of 1 mg per 5 ml (45). Fecal resuspension was thoroughly mixed and centrifuged for 5 min at 13,000 rpm to collect supernatant. Collected serum and fecal resuspension samples were stored at Ϫ80°C until use. Animal studies in this project complied with the Animal Welfare Act by following the 1996 National Research Council guidelines (27) and were approved and supervised by a state veterinarian and South Dakota State University's Institutional Animal Care and Use committee.
Antibody titration and neutralization of mouse serum and fecal samples. Anti-STa and anti-LT antibodies in mouse serum and fecal resuspension samples (1:50 dilution) were titrated as described previously (46) . Anti-STa antibodies were titrated in an STa enzyme-linked immunosorbent assay (ELISA) by using STa ovalbumin conjugates as coating antigens (1.25 ng/well), and anti-LT antibodies were titrated in a standard GM1 ELISA using cholera toxin (CT; Sigma) as the antigen (400 ng GM1 and 100 ng CT/well). HRP-conjugated goat antimouse IgG and IgA (1:3,300; Sigma) were used as the secondary antibodies. The cutoff optical densities (ODs) in ELISA were defined as the A 405 background plus 0.4. The dilution that gave ODs above the cutoff was calculated for antibody titers, which were expressed as the log 10 (46).
Antibody neutralizing activity was examined in T-84 cells with cGMP and cAMP EIA kits (Assay Design). Neutralizing activity against STa was assessed by using 2 ng of STa toxin (diluted in 150 l of Dulbecco's modified Eagle medium [DMEM]-F12 medium) and a cGMP kit, and activity against CT was assessed with 10 ng of CT and a cAMP kit, as described previously (46) . Statistical analysis. Data were analyzed by using the mixed procedure (SAS for Windows, version 8; SAS Institute, Cary, NC), adjusting for multiple comparison by Bonferroni's correction. Results were expressed as means Ϯ standard deviations. Student's t test was used to compare the treatment groups. Calculated P values of Ͻ0.05 were regarded as significant when treatments were compared at two-tailed distribution and two-sample equal or unequal variance.
RESULTS
Five E. coli strains expressing fusions 1b to 5b were constructed. The native eltAB and estA genes were first cloned to generate an LT recombinant strain (8460) and an STa recombinant strain (8325), and then we mutated the cloned gene to generate an LT 192 mutant strain (8543) and an STa 13 mutant strain (8405) ( Table 1) . Fusing the mutated STa 13 gene, which encodes the mature peptide, to the mutated LT 192 genes encoding the mature A and B subunits with different linkers or at different locations yielded five fusions, designated 1b to 5b (Fig. 1A) . Fusions 1b and 2b had the mutated STa 13 sequently, plasmids were constructed, and then E. coli BL21 was transformed with the toxoid fusion-containing plasmids to yields five fusion-containing strains: 8750 (fusion 1b), 8751 (fusion 2b), 8752 (fusion 3b), 8753 (fusion 4b), and 8754 (fusion 5b) ( Table 1) . We also transformed BL21 with the pET28␣vector to generate a negative-control strain, 8955. LT 192 -STa 13 fusion proteins were expressed in fusion 1b to 5b strains. Total protein extracts from equivalent amounts of cells of strains carrying fusions 1b to 5b were used to examine fusion protein expression in a 10% SDS-PAGE gel with anti-CT and anti-STa sera. A dominant band over 40 kDa, which is equivalent to the molecular size of a monomeric LT AB192 -STa 13 plus a 6His tag, was detected from each strain with anti-CT serum (Fig. 1B) and purified anti-STa antibodies (Fig.  1C) . No fusion proteins were detected from the negative-control strain.
LT 192 -STa 13 fusion proteins expressed in fusion 1b to 5b strains were not toxic. None of the five fusion proteins showed toxic activity in stimulating cAMP and cGMP levels in T-84 cells or fluid accumulation in ligated-gut-loop assay (Table 3) . Neither the cAMP nor the cGMP levels in the T-84 cells incubated with culture growth of the fusion strains showed any significant differences compared to levels in cells incubated with the negative-control strain. In contrast, a significant increase of cAMP level (Ͼ200 pmol/ml) was detected in the cells incubated with the LT strains 9060 and H10407, and a significance increase of cGMP (Ն20 pmol/ml) was detected in the T-84 cells incubated with and the STa strains 9064 and H10407. Similarly, no fluid stimulation occurred in loops incubated with culture of the fusion strains or the negative strain. But the loops incubated with H10407 culture had a fluid accumulation ratio of 0.33 Ϯ 0.13, a clear sign of positive toxic activity.
Purified 6His-tagged LT 192 -STa 13 fusion proteins facilitated STa immunogenicity. Anti-STa and anti-LT antibodies were detected in the mice immunized with purified 6His-tagged fusion 1b to 5b proteins (Fig. 2) . Antibody titration showed that anti-STa IgG antibodies were detected in serum and fecal samples from the immunized mice, but anti-STa IgA antibodies were detected only in the fecal samples from the immunized mice. Anti-STa IgG antibodies in sera of the mice immunized with fusion 1b, 2b, 3b, 4b, and 5b proteins were detected at titers (log 10 ) of 1.73 Ϯ 0.32, 1.75 Ϯ 0.31, 1.73 Ϯ 0.47, 1.69 Ϯ 0.41, and 1.63 Ϯ 0.56, respectively ( Fig. 2A) . Anti-STa IgA antibodies in the fecal sample from the mice immunized with fusion 1b, 2b, 3b, 4b, and 5b proteins were detected at titers of 1.75 Ϯ 0.31, 1.72 Ϯ 0.36, 1.59 Ϯ 0.12, a Supernatants of overnight-grown cultures from an equivalent amount of cells from each strain were used in cAMP and cGMP ELISAs, and 2 ϫ 10 9 CFU of overnight-grown culture from each fusion strain was injected into ligated loops in the porcine ligated-gut-loop assay. ETEC strain H10407 (LT ϩ STa ϩ ) was used as a positive control, and 8955 was used as a negative control. In addition, the LT Antibodies in fecal samples from the immunized mice showed neutralizing activity against STa and CT. Anti-STa antibodies, mainly from fecal resuspension samples from immunized mice, showed neutralizing activity in vitro (Fig. 3A) . After incubation with the fecal samples from the immunized mice, 2 ng STa showed no significant increase of intracellular cGMP levels in T-84 cells. The intracellular cGMP concentrations in cells treated with STa mixed with fecal resuspension (1:5 dilution) from the mice immunized with fusion 1b, 2b, 3b, 4b, and 5b proteins were 3.7 Ϯ 1.4, 3.8 Ϯ 1.1, 3.4 Ϯ 0.8, 3.0 Ϯ 0.8, and 3.2 Ϯ 0.5 pmol/ml, respectively. These cGMP levels were significantly lower (P Ͻ 0.01) than levels in cells treated with 2 ng STa mixed with fecal resuspension from the control mice (9.1 Ϯ 0.2 pmol/ml). These differences remained significant even after the Bonferroni adjustment, as the calculated P values were still less than 0.01. On the other hand, antibodies in serum samples from immunized mice showed limited neutralizing activities. The cGMP level in T-84 cells treated with STa mixed with serum samples from immunized mice, except those from mice immunized with fusion 1b (P ϭ 0.04; however, this significance in difference was lost after the Bonferroni adjustment), showed no significant differences compared to that in cells treated with STa and serum samples from the control mice (Fig. 3A) . The concentration of cGMP in T-84 cells treated with STa and cell culture medium was 9.2 Ϯ 0.4 pmol/ml.
Anti-LT antibodies from serum and fecal samples showed neutralizing activity against CT (Fig. 3B) . After being incubated with serum and fecal resuspension samples from mice immunized with fusion 1b, 2b, 4b, or 5b, CT stimulated significantly lower cAMP levels in T-84 cells. The cAMP levels (pmol/ml) in cells treated with CT and serum from mice immunized with fusions 1b, 2b, 3b, 4b, and 5b were 5.1 Ϯ 2.4 (P ϭ 0.007), 4.0 Ϯ 0.75 (P ϭ 2E-06), 5.4 Ϯ 3.1 (P ϭ 0.03), 3.7 Ϯ 1.3 (P ϭ 3.6E-05), and 4.8 Ϯ 1.3 (P ϭ 0.001), respectively. The cAMP level in cells treated with CT and serum samples from control mice was 9.7 Ϯ 0.7, and the level in cells treated with CT and cell culture medium was 12 Ϯ 0.71 pmol/ml. In another cAMP ELISA study, T-84 cells treated with fecal samples from immunized mice showed no significantly increased cAMP levels. The cAMP levels in cells treated with CT and fecal resuspension samples from mice immunized with fusions 1b, 2b, 4b, and 5b were 7.5 Ϯ 3.2, 7.5 Ϯ 3.5, 5.7 Ϯ 3.8, and 8.1 Ϯ 5.4 (pmol/ml), respectively. These cAMP levels were significantly lower than those in cells incubated with CT and the fecal samples from the control groups (18.1 Ϯ 2.3; P Ͻ 0.01) and those in cells treated with CT and cell culture medium (20.8 Ϯ 3.9; P Ͻ 0.01). In contrast, the cAMP level in cells treated with CT and fecal resuspension from the mice immunized with fusion 3b was 10.7 Ϯ 9.6, which was not significantly different from the level in the cells incubated with CT and the fecal samples from the control mice (P ϭ 0.18). 
DISCUSSION
Data from this study indicated that the human-type STa 13 toxoid became immunogenic when fused to the full-length toxoid LT 192 and that the LT 192 -STa 13 fusion antigens elicited antitoxin antibodies neutralizing STa toxin and CT in T-84 cells. These results are concordant with the findings from our previous study in which porcine-type STa toxoids became immunogenic and elicited neutralizing anti-STa antibodies after being fused to a full-length porcine LT 192 protein (46) . Data from this study confirm that STa toxoids, not just native STa or shorter STa peptides, can become immunogenic after being fused to a strongly immunogenic carrier protein, and this provides useful information for future development of toxoid vaccines against ETEC.
Native STa proteins were demonstrated to become immunogenic when they were linked to a carrier protein chemically (22) or genetically (7, 16, 24, 28, 31, 32) . It was further reported that antibodies produced in mice immunized with the LT B -STa fusion neutralized native STa toxin in an infant suckling mouse assay (7). However, concerns regarding safety of the highmolecular-weight carrier proteins and toxicity retained by the native STa or LT A protein in these fusion products negatively affected their applications in vaccine development. In contrast, LT and STa toxoids are safe antigens; thus, toxoid fusion antigens are better candidates for antitoxin vaccines against ETEC infection. Data from this study showed that the LT 192 -STa 13 fusions (in the format of a single protein) do not stimulate an increase of cAMP and cGMP in T-84 cells or cause fluid secretion in ligated porcine gut loops. This suggests that LT 192 -STa 13 fusions are safe antigens and can be used in future ETEC subunit vaccine development.
Although it has been suggested that STa needs to retain some toxicity in order to become immunogenic when carried by a carrier protein (3, 35, 36) , other studies clearly indicated that nontoxic STa antigens in fusion formats elicited neutralizing antibodies (18, 19, 20, 28, 46) . It was demonstrated that synthetic mutated pSTa (pSTa N11P , pSTa Y18N ), when chemically cross-linked to an LT B subunit or porcine IgG molecules, elicited anti-STa antibodies. Moreover, these anti-STa antibodies provided protection against ETEC infection (18, 19, 20) . Data from the present study further confirm that the STa 13 toxoid, when fused to a carrier protein, elicits neutralizing anti-STa antibodies. It should be noted that we observed antiSTa IgG in serum and anti-STa IgG and IgA in fecal samples from immunized mice, but only antibodies in fecal samples clearly exhibited neutralizing activity against purified STa toxin. That could suggest that anti-STa IgA antibodies play a more important role in neutralizing STa toxin. Interestingly, an early study indicated that sera from mice immunized with the LT B -STa fusion antigen or crude cell lysates of the construct expressing this fusion partially neutralized STa toxin in the suckling mouse assay (7) . Clearly, more studies are needed to determine the classes and specificity of anti-STa antibodies that neutralize STa toxin. Data from this study suggest that both serum and fecal samples should be examined for neutralizing activity against STa toxin for better assessment on toxoid fusion antigenicity. Intestinal wash samples from the immunized mice were also used in antibody titration and antibody neutralization assays in this study. However, due to high background in ELISAs, these data were not included in final analyses.
Different strategies have been explored to fuse STa antigens at different locations or to different carrier proteins. Native STa or shorter STa peptides were fused at the C terminus of LT B (7), the C terminus of the cholera toxin subunit CT B (2, 6) , the N terminus of the LT B subunit (16, 31) , and the C terminus of the LT A subunit (32) . However, anti-STa immunogenicity in these fusion constructs had not been compared. Thus, it was unknown which fusion product is the best candidate for future antitoxin vaccine development. In this study, we fused the STa 13 toxoid at four different locations-the C and N termini of LT 192 , between the A1 and A2 fragments, and between the A and B subunits of LT 192 -and attempted to identify an optimum fusion strategy. However, data from this study are inconclusive. Mice immunized with fusions 1b and 2b, fusions with STa 13 at the C terminus of LT 192 , elicited slightly higher titers of anti-STa (and anti-LT) serum IgG and fecal IgA antibodies. However, piglets immunized with fusions 1b and 2b showed higher titers of anti-STa IgA in fecal samples but lower titers of anti-STa IgG antibodies in the serum samples (data not shown). It is unknown to us whether this inconsistency is caused by the difference in immunization routes (intraperitoneal in mice and intramuscular in piglets). On the other hand, data from this study indicated that fusion 3b (STa 13 at the N terminus of LT 192 ) elicited lower titers of anti-STa antibodies, especially in fecal samples. In addition, fusing STa 13 at the N terminus of LT 192 (to form a single antigen) negatively affected anti-LT immunogenicity. Moreover, anti-mouse antibodies elicited by fusion 3b exhibited lower neutralizing activity against toxins. The addition of the 6His tag and the STa 13 peptide at the N terminus could alter LT peptide conformation and likely affect anti-LT immunogenicity.
Only the STa P13F toxoid was used for constructing toxoid fusions in this study. STa P13F is homologous to pSTa P12F , and pSTa P12F showed greater enhancement of STa immunogenicity when fused to pLT 192 toxoid than pSTa N11K or pSTa A13Q did (46) . We assumed that the analogous hSTa N12K and hSTa A14Q toxoids would be less effective in eliciting anti-STa antibodies than STa 13 , when fused to LT 192 . However, STa 12 and STa 14 should be investigated as candidates for potential toxoid vaccines. Indeed, only two other STa toxoids, STa C7A and STa C18A , were studied for potential in vaccine development (28) . More studies to thoroughly examine other STa toxoids, especially those derived from substitution of amino acid residues inside the toxicity domain region, will be helpful in selecting optimum STa toxoids for developing effective toxoid vaccines against ETEC.
Three independent immunization studies with a total of 10 mice for each toxoid fusion were conducted to assess antigenicity of each individual antigen in this study. Conclusions drawn from the mouse immunization studies should be reliable. Results from this study confirmed that an STa toxoid became immunogenic when fused to LT 192 toxoid and elicited neutralizing antitoxin antibodies. This provides helpful information for developing safe and effective toxoid vaccines against ETEC diarrhea.
